PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: Potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia

Journal of Psychopharmacology

Volumn 25, Issue 6, 2011, Pages 792-800

  Sood, Pooja ^a   Idris, Nagi F ^b   Cole, Susan ^c   Grayson, Ben ^b   Neill, Joanna C ^b   Young, Andrew Mj ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

D4 receptors; novel object recognition; PD168077; phencyclidine; recognition memory

Indexed keywords

N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; PHENCYCLIDINE; BENZAMIDE DERIVATIVE; DOPAMINE 4 RECEPTOR; N ((4 (2 CYANOPHENYL) 1 PIPERAZINYL)METHYL) 3 METHYLBENZAMIDE; N-((4-(2-CYANOPHENYL)-1-PIPERAZINYL)METHYL)-3-METHYLBENZAMIDE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; EXPLORATORY BEHAVIOR; FEMALE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; SCHIZOPHRENIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; PERCEPTIVE DISCRIMINATION; PSYCHOLOGY; RAT STRAIN;

ANIMALS; BENZAMIDES; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; PHENCYCLIDINE; PIPERAZINES; RATS; RATS, INBRED STRAINS; RECEPTORS, DOPAMINE D4; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIC PSYCHOLOGY;

EID: 79960496515     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110387840     Document Type: Article

References (59)

1. Abdul-Monim Z, Neill JC, Reynolds GP. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol. 2007 ; 21: 198-205 (Pubitemid 46280471)
2. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res. 2006 ; 169: 263-273
3. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry. 1978 ; 135: 1081-1084 (Pubitemid 8395441)
4. Berlyne DE. Novelty and curiosity as determinants of exploratory behavior. Br J Psychol. 1950 ; 41: 68-80
5. Bernaerts P, Tirelli E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav Brain Res. 2003 ; 142: 41-52 (Pubitemid 36677589)
6. Bertaina-Anglade V, Enjuanes E, Morillon D, Drieu la Rochelle C. The object recognition task in rats and mice: A simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods. 2006 ; 54: 99-105 (Pubitemid 44308867)
7. Browman KE, Curzon P, Pan JB, Molesky AL, Komater VA, Decker MW, et al. A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacol Biochem Behav. 2005 ; 82: 148-155 (Pubitemid 41423498)
8. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007 ; 33: 1120-1130 (Pubitemid 47347922)
9. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963 ; 20: 140-144
10. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: A placebo-controlled trial. Biol Psychiatry. 2004 ; 55: 445-451 (Pubitemid 38338530)
11. Coyle JT. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 ; 26: 365-384
12. Dere E, Huston JP, de Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev. 2007 ; 31: 673-704 (Pubitemid 46670336)
13. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1. Behavioural data. Behav Brain Res. 1988 ; 31: 47-59
14. Floresco SB, Geyer MA, Gold LH, Grace AA. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull. 2005 ; 31: 888-894 (Pubitemid 41437783)
15. Glase SA, Akunne HC, Georgic LM, Heffner TG, MacKenzie RG, Manley PJ, et al. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. J Med Chem. 1997 ; 40: 1771-1772 (Pubitemid 27251265)
16. Gold JM, Hermann BP, Randolph C, Wyler AR, Goldberg TE, Weinberger DR. Schizophrenia and temporal lobe epilepsy. A neuropsychological analysis. Arch Gen Psychiatry. 1994 ; 51: 265-272 (Pubitemid 24127298)
17. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res. 2007 ; 184: 31-38 (Pubitemid 47404650)
18. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull. 2009 ; 35: 549-562
19. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, et al. (2010) Sertindole improves subchronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms Psychopharmacology (Berl) 208: 23-36.
20. Itil T, Keskiner A, Kiremitci N, Holden JM. Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J. 1967 ; 12: 209-212
21. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 ; 148: 1301-1308
22. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999 ; 20: 201-225 (Pubitemid 29067401)
23. Jentsch JD, Taylor JR, Redmond Jr, Elsworth JD, Youngren KD. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine- induced object retrieval/detour deficits in monkeys. Psychopharmacology. 1999 ; 142: 78-84 (Pubitemid 29196067)
24. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006 ; 63: 1079-1087 (Pubitemid 44498387)
25. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007 ; 64: 633-647 (Pubitemid 46878665)
26. Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry. 1997 ; 54: 567-572 (Pubitemid 27258555)
27. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999 ; 288: 774-781 (Pubitemid 29119694)
28. Lahti RA, Roberts RC, Tamminga CA. D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport. 1995 ; 6: 2505-2512
29. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. J Psychopharmacol. 2007 ; 21: 283-301 (Pubitemid 46934046)
30. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006 ; 32: 715-723 (Pubitemid 44412859)
31. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron. 2000 ; 28: 325-334
32. McLean SL, Beck JP, Woolley ML, Neill JC. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res. 2008 ; 189: 152-158
33. McLean SL, Idris NF, Woolley ML, Neill JC. D1 receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of cognition in schizophrenia. Eur Neuropsychopharmacol. 2009 ; 19: 440-450
34. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008 ; 172: 177-197
35. Meltzer HY, McGurk SR. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999 ; 25: 233-255 (Pubitemid 29272503)
36. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005 ; 5: 101-106 (Pubitemid 40124542)
37. Mouri A, Noda A, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007 ; 51: 173-184 (Pubitemid 47176714)
38. Neill JC, Barnes B, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010 ; 00 ( 00 ):
39. Newman-Tancredi A, Heusler P, Martel J-C, Ormiere A-M, Leduc N, Cussac D. Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. Int J Neuropsychopharmacol. 2008 ; 11: 293-307 (Pubitemid 351482503)
40. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999 ; 33: 523-533
41. Rivera A, Peñafiel A, Megías M, Agnati LF, López-Téllez JF, Gago B, et al. Cellular localization and distribution of dopamine D4 receptors in the rat cerebral cortex and their relationship with the cortical dopaminergic and noradrenergic nerve terminal networks. Neuroscience. 2008 ; 155: 997-1010
42. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch Gen Psychiatry. 1991 ; 48: 618-624
43. Schiapparelli L, Simon AM, Del Rio J, Frechilla D. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: Correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology. 2006 ; 50: 897-907 (Pubitemid 43737006)
44. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975 ; 188: 1217-1219
45. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994 ; 15: 264-270 (Pubitemid 24210734)
46. Snigdha S, Li Z, Dai J, Shahid M, Neill JC, Meltzer H Program No. 791.4/TT40. 2008 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, ; 2008 :
47. Snigdha S, Neill JC. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats: A preliminary investigation. Behav Brain Res. 2008a ; 187: 489-494
48. Snigdha S, Neill JC. Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A 1018 receptors. Behav Brain Res. 2008b ; 191: 26-31
49. Snigdha S, Neill J, Shahid M, Cruise L, Henry B. Brain-derived neurotrophic factor downregulation in rat brain following sub-chronic phencyclidine administration. Eur Neuropsychopharmacol. 2007 ; 17 (Suppl 4). S258 - S258
50. Sood P, Cole S, Fraier D, Young AMJ. Behavioural and neurochemical effects of D4 receptor agonist; PD168077: Measurement of absolute brain concentrations of dopamine using microdialysis in freely moving rats. Br Neurosci Assoc Abstr. 2009 ; 20: 113-113
51. Sutcliffe JS, Marshall K, Neill JC. Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav Brain Res. 2007 ; 177: 117-125 (Pubitemid 46054189)
52. Tamminga CA, Kane JM. Olanzapine (Zyprexa): Characteristics of a new antipsychotic. Expert Opin Investig Drugs. 1997 ; 6: 1743-1752 (Pubitemid 27488038)
53. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere M-E, Papillon-Downey C. Placebo-controlled study of the D4/5-HT(2A) antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry. 1999 ; 156: 419-425 (Pubitemid 29124164)
54. Wang X, Gu Z, Zhong P, Chen G, Feng J, Yan Z. Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure. Mol Cell Neurosci. 2006 ; 31: 15-25 (Pubitemid 43049898)
55. Winters BD, Saksida LM, Bussey TJ. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev. 2008 ; 32: 1055-1070
56. Wong AHC, Van Tol HHM. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharm Biol Psychiatry. 2003 ; 27: 1091-1099 (Pubitemid 37464955)
57. Woolley ML, Waters KA, Reavill C, Bull S, Lacroix LP, Martyn AJ, et al. Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol. 2008 ; 19: 765-776
58. Yuen EY, Yan Z. Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. J Neurosci. 2009 ; 29: 550-562
59. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009 ; 122: 150-202